China's Hansoh Pharmaceutical has signed a partnership and licensing agreement with Roche covering a portfolio of antibody-drug conjugate cancer programmes, potentially worth more than $15 billion. Hansoh will receive $400 million upfront and $110 million on the first anniversary, while keeping rights in Greater China.
<p>Roche, one of the world's largest drugmakers, has struck a licensing deal with China's Hansoh Pharmaceutical that could be worth more than $15 billion, the latest sign of how Chinese biotech has become a central source of innovation for global pharmaceutical companies.</p><p>Under the agreement announced on Monday, October 19, Hansoh will receive an upfront payment of $400 million and a further $110 million on the first anniversary of the deal, according to Reuters. Additional milestone payments, the amounts of which were not specified, could take the total value above $15 billion.</p><p>The partnership covers a portfolio of antibody-drug conjugate (ADC) programmes, an advanced class of targeted cancer therapies. The agreement is with F. Hoffmann-La Roche, Roche's main operating company.</p><h2>How the deal works</h2><p>Hansoh will lead early development of the programmes until global Phase Ia clinical trials are complete. Roche will then take over worldwide development and commercialisation. Hansoh retains rights in mainland China, Hong Kong, Macau and Taiwan, and has the option to co-develop up to two programmes outside those markets.</p><p>Roche said the collaboration, combined with its own research, will allow it to make ADCs a central part of its next-generation oncology strategy. The two companies have previously partnered on treatments for colorectal cancer.</p><p>The structure, with a substantial upfront payment and large back-loaded milestones, is typical of licensing deals in the pharmaceutical industry. Milestone payments are made only if drug candidates hit specific development, regulatory and sales targets, so the headline value represents a maximum rather than a guaranteed amount.</p><img src="/api/files/1792481108030-7f6fff9c528beae6e3092cfe.webp" alt="678777dc-ccf5-4981-899d-2461a2bd305c.png"><h2>What ADCs are</h2><p>Antibody-drug conjugates are often described as "guided missiles" for cancer. They combine an antibody that recognises a specific protein on the surface of cancer cells with a potent chemotherapy drug, joined by a chemical linker. The antibody delivers the toxic payload directly to tumour cells, aiming to kill them while sparing healthy tissue and reducing the side effects of traditional chemotherapy.</p><p>ADCs have become one of the most active areas of cancer drug development over the past decade. Several have become blockbuster products, and drugmakers have paid billions to acquire or license promising candidates. Roche already sells two approved ADCs, Kadcyla for breast cancer and Polivy for lymphoma. Analysts expect the two products to generate combined sales of about 3.5 billion Swiss francs, or $4.3 billion, in 2026, according to LSEG-based estimates.</p><h2>Roche's pipeline pressures</h2><p>The deal reflects pressures facing Roche and other large pharmaceutical companies. Several of Roche's older blockbuster drugs face patent expirations, which allow cheaper generic and biosimilar competitors to enter the market. Its late-stage pipeline is expected to be relatively thin until the end of the decade, increasing the need to bring in external innovation.</p><p>Roche has been active in licensing deals this year. In August, its Genentech unit signed an ADC deal with DualityBio worth up to $1 billion. Earlier this month, Roche signed an obesity drug licence with Rona Therapeutics worth up to $1.16 billion, and in January it paid $100 million upfront for a non-exclusive patent licence from Structure Therapeutics covering oral weight-loss drugs.</p><h2>China's biotech moment</h2><p>The Hansoh agreement is part of a broader wave of deals in which Western drugmakers are licensing drug candidates from Chinese companies. Drugmakers have struck more than a dozen such licensing deals with Chinese firms in the past year, according to Reuters. AstraZeneca's obesity pact with CSPC in January was valued at $18.5 billion, and Bristol Myers Squibb's multi-programme alliance with Jiangsu Hengrui in May was valued at $15.2 billion.</p><p>Chinese biotech companies have become increasingly competitive in drug discovery and early development. They benefit from large pools of scientific talent, government support for the life sciences, fast clinical trial recruitment and lower costs than in the United States or Europe. In areas such as ADCs, bispecific antibodies and cell therapies, Chinese companies have produced candidates that global drugmakers consider among the most promising in the world.</p><p>The trend has raised questions in Washington, where some lawmakers have expressed concern about US dependence on Chinese biotech and the transfer of value to China. Proposed legislation has sought to restrict some business with certain Chinese biotech firms. So far, however, the commercial logic of licensing promising drugs has continued to drive deal-making.</p><h2>What it means for India</h2><p>The deal holds lessons for India's pharmaceutical industry. India is the world's largest supplier of generic medicines by volume and a major producer of vaccines, but it has been slower than China to develop novel drugs that can command large licensing fees. Indian companies have traditionally focused on manufacturing high-quality, low-cost generics rather than discovering new molecules.</p><p>That is beginning to change. Several Indian drugmakers and biotech startups are investing in innovative research, including in biologics, ADCs and cell and gene therapies. The government has introduced schemes to promote research and innovation in pharmaceuticals. But the scale of China's success in out-licensing shows how far India must go to compete in the high-value end of the industry.</p><h2>The economics of licensing</h2><p>For Chinese biotech companies, licensing deals with global pharmaceutical groups offer several advantages. Upfront payments provide immediate cash to fund research, milestone payments create potential long-term income, and partnerships with established drugmakers bring expertise in late-stage clinical trials, regulatory approvals and global commercialisation, which smaller companies often lack.</p><p>For Western drugmakers, licensing from China can be a cost-effective way to access innovative drug candidates at an early stage. Development costs in China are typically lower, and Chinese companies have shown they can move quickly from discovery to clinical trials. The result has been a steady flow of deals that has transformed China from a market for medicines into a significant source of them.</p><h2>What comes next</h2><p>For Hansoh, the deal provides significant upfront cash and potential long-term income, while allowing it to retain rights in its home market. For Roche, it adds a portfolio of potentially important cancer therapies at a time when it needs to replenish its pipeline.</p><p>For patients, the hope is that the collaboration will produce more effective and better-tolerated cancer treatments. For the global pharmaceutical industry, the deal is further evidence that some of the most promising future medicines are being discovered in China, and that the world's largest drugmakers are willing to pay handsomely to access them.</p>
“We are witnessing the birth of ‘Statist Silicon’—where the location of a transistor’s manufacture is as important as its clock speed.”
The Rise of Regional Fabric
